Christos S. Mantzoros, MD, DSc, PhD h.c. mult., is a Professor of Medicine at Harvard Medical School and an Adjunct Professor at Chobanian and Avedisian School of Medicine. He has also served as a Professor of Environmental Health at the Harvard School of Public Health. He currently serves as the Chief of Endocrinology, Diabetes and Metabolism at the Boston VA Healthcare System and the Director of the Human Nutrition Unit of the Division of Endocrinology Diabetes and Metabolism at Beth Israel Deaconess Medical Center. Dr. Mantzoros has been the editor of two books (one on “Diabetes and Obesity” and one on “Nutrition and Metabolism” with more than two editions each). His research has resulted in more than 800 publications in Medline, including more than 150 publications under the collaborative Look Ahead Research Group, more than 200 chapters and reviews, with more than 72,000 citations with a Hirsch Index H=121. Dr. Mantzoros is also the director for the VA Boston Healthcare System fellowship program with Boston University Medical Center (BUMC), which offers one dedicated fellowship position through BUMC, but also allows any fellow at BUMC or Harvard affiliated fellowship programs the opportunity to rotate through the VA Boston Healthcare System. He has served as a Board Member or an advisor or head of the Scientific Advisor Board of non for profit foundations as well as governmental and non-governmental entities. He is the Editor-in-Chief of the journal Metabolism and is on the editorial board of several scientific journals worldwide. For his research discoveries and public health service Dr. Mantzoros has received four honorary PhDs, the Alexander Technological Institute of Thessaloniki has named their nutrition laboratories after his name and several Universities worldwide have awarded Dr. Mantzoros honorary Professorships and visiting Professorships. He has or is supervising PhD thesis work in several nations worldwide (Sweden, Germany, Greece, USA etc) and is actively collaborating with many research groups worldwide. He has mentored more than 160 young scientists who currently hold key positions in clinical medicine, academia, industry as well as governmental agencies and nongovernmental organizations. Dr. Mantzoros has been elected a member of ASCI and a Fellow of the American College of Physicians and the American Association of Clinical Endocrinology. He has been given several awards including but not limited to awards by: the American Association of Clinical Endocrinology (Frontiers in Science Award), the American Diabetes Association (Novartis Award in Diabetes and Metabolic Diseases), the North American Association for the Study of Obesity / the Obesity Society (Lilly Award), the American Society for Nutrition (Mead Johnson Award), the HypoCCS award in Paris, France, the Humboldt Foundation of Germany (the Wilhelm Friedrich Bessel Award), by the American Federation of Medical Research (the Outstanding Investigator Award), by the American Physiological Society (FASEB, the Berson Award Lecture), by the New England Hellenic Medical and Dental Association (Hygeia award) etc. He has also received the BIDMC, Harvard Medical School, award for excellence in Mentoring. He will be receiving the 2018 European Society of Endocrinology Geoffrey Harris Prize.
- Professor, Medicine, Harvard Medical School
- Director, Human Nutrition Unit, Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center
- Endocrinology, VA Boston Healthcare System
- University of Athens, MD
- University of Athens, DSc
- Harvard Medical School, MMS/MMSc
- Harvard School of Public Health, MSc
- Published on 7/25/2022
Kelesidis T, Mantzoros CS. Cross-talk between SARS-CoV-2 infection and the insulin/IGF signaling pathway: Implications for metabolic diseases in COVID-19 and for post-acute sequelae of SARS-CoV-2 infection. Metabolism. 2022 Sep; 134:155267. PMID: 35901934.
- Published on 7/9/2022
Bouzoni E, Perakakis N, Connelly MA, Angelidi AM, Pilitsi E, Farr O, Stefanakis K, Mantzoros CS. PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses. Metabolism. 2022 Sep; 134:155265. PMID: 35820631.
- Published on 7/5/2022
Valenzuela-Vallejo L, Guatibonza-García V, Mantzoros CS. Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation? Metabolism. 2022 Nov; 136:155248. PMID: 35803320.
- Published on 7/1/2022
Valenzuela-Vallejo L, Mantzoros CS. Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). Metabolism. 2022 Sep; 134:155246. PMID: 35780909.
- Published on 7/1/2022
DeMarsilis A, Mantzoros CS. The continuum of insulin development viewed in the context of a collaborative process toward leveraging science to save lives: Following the trail of publications and patents one century after insulin's first use in humans. Metabolism. 2022 Oct; 135:155251. PMID: 35787414.
- Published on 6/29/2022
Aponte Becerra L, Galindo Mendez B, Khan F, Lioutas V, Novak P, Mantzoros CS, Ngo LH, Novak V. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial. Arch Diabetes Obes. 2022; 4(2):403-415. PMID: 35903156.
- Published on 6/28/2022
Valenzuela-Vallejo L, Chrysafi P, Mantzoros CS. Liraglutide-induced effects on energy intake and glycemic profile are independent of total and intact GDF-15 levels in subjects with obesity and diabetes. Diabetes Metab. 2022 Sep; 48(5):101369. PMID: 35777691.
- Published on 6/11/2022
Valenzuela-Vallejo L, Chrysafi P, Bello-Ramos J, Bsata S, Mantzoros CS. Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity. Metabolism. 2022 08; 133:155237. PMID: 35700837.
- Published on 5/18/2022
Sanoudou D, Gkouskou KK, Eliopoulos AG, Mantzoros CS. Epitranscriptomic challenges and promises in metabolic diseases. Metabolism. 2022 Jul; 132:155219. PMID: 35597274.
- Published on 5/15/2022
Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022 Aug; 133:155217. PMID: 35584732.
View 622 more publications: View full profile at BUMC